• SynAct Pharma flagged new preclinical results for resomelagon, a phase 3-ready rheumatoid arthritis candidate, for presentation in September 2026.
• Data in an osteoarthritis mouse model suggest the drug reduced inflammation, limited joint damage, eased pain, and showed potential disease-modifying activity.
• In a Pseudomonas pneumonia mouse model, resomelagon lowered mortality and lung injury, supporting use as an add-on to antibiotics.
• The readouts broaden the program beyond rheumatoid arthritis into osteoarthritis and severe bacterial infections, supporting pipeline expansion and partnering optionality.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.